Phase Forward's Clinical Trials Signal Detection (CTSD) Product Wins Prestigious Bio-IT World Best Practices Award

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that its Lincoln Safety Group’s Clinical Trials Signal Detection (CTSD™) product garnered a prestigious "Best Practices” award at the recent Bio-IT World Life Sciences Conference and Expo in Boston. Today’s announcement marks the second time in three years CTSD has been honored by the conference and expo; in 2006, CTSD took home a Best of Show award. As in 2006, the 2008 award was given to CTSD in the "Clinical Trials and Research” category. This year’s award recognizes the CTSD implementation at GlaxoSmithKline. GSK partnered with the Phase Forward Lincoln Safety Group in 2006 and collaborated with Lincoln’s development team to design a Safety Review interface which enhances Clinical Safety users’ ability to review data from both completed and ongoing studies. The Safety Review interface combined with CTSD’s automated screening on adverse events, laboratory, vital signs and electrocardiogram (ECG) data can help facilitate timely detection and evaluation of safety signals. "We are gratified by the recognition Bio-IT World Life Sciences Conference and Expo has again given our CTSD product,” said Phase Forward Lincoln Safety Group President Chan Russell. "We congratulate our co-recipient GSK for their innovative use of CTSD.” "We are honored once again to be in the spotlight at Bio-IT World. In 2005, GSK and the Lincoln Safety Group won the award for our post-marketing safety signal detection tool and we said we would be back with a clinical trial signal detection system,” said Trevor Gibbs, GSK’s Senior Vice-President, Medical Governance and Pharmacovigilance. "This award is nicely aligned with GSK’s deployment of the CTSD tool. We look forward to continuing our successful partnership with the Lincoln Safety Group.” Bio-IT World is an industry-leading publication addressing the technologies driving discovery, development and clinical trials. Bio-IT World’s Best Practices Awards Program, established in 2003, recognizes teams for their novel and innovative uses of technology to improve the efficiency and economics of R&D, drug discovery, and clinical research and trials. The quality and breadth of the 2008 program is underscored by the record 54 entries. For more information on Bio-IT World, please visit: www.bio-itworld.com. For more information on The Life Sciences Conference and Expo, please visit: http://www.bio-itworldexpo.com/. About Bio-IT World, Inc. Bio-IT World (www.bio-itworld.com), the flagship publication of Cambridge Healthtech Institute (CHI), is the leading source of news on technology and strategic innovation in drug discovery, development, and clinical trials. Bio-IT World explores the tools and results of predictive biology as the industry adapts to the new world of personalized medicine. Bio-IT World has won 34 national and regional awards, more than any other magazine covering the life sciences industry. CHI offers a suite of published resources through a new division—Cambridge Healthtech Media Group—that includes Bio-IT World magazine, numerous topic-specific eNewsletters, white papers, webcasts, podcasts, conferences, and the Bio-IT World Best Practices Awards. The magazine is based in Needham, MA. About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), phase I clinic automation (LabPas(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Empirica(TM) Trace) and applied data standards (WebSDM(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com. Cautionary Statement Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward’s customers and the manner in which they conduct business, changes in commonly used industry standards, the possibility that customers’ needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.